Cytosorbents (CTSO) Osake Kurssi
Cytosorbents Kurssi
Liikevaihto on kasvanut 64,1 % vuodessa viimeisten 14 vuoden aikana 37,06 M USD:een. Cytosorbentsn nettomarginaali on nyt −22,1 %, noussut −61,2 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 5,10 USD, eli yli nykyhintaa 12,3 %. 8 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Cytosorbents osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Cytosorbents liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Cytosorbents -osakkeesta
The business model of Cytosorbents Corp involves the development and commercialization of technologies for blood purification. The company specializes in the production of devices that are designed to remove harmful substances from the bloodstream, including toxins, cytokines, and pathogens. This process is aimed at improving patient outcomes in various medical conditions, such as sepsis, cytokine storm, and other critical illnesses. Cytosorbents Corp's innovative products, like the CytoSorb® Therapy, offer healthcare professionals a versatile tool to help reduce inflammation and manage complications associated with excessive immune response. Overall, the company focuses on advancing blood purification technologies to enhance patient care and address unmet medical needs efficiently.
Cytosorbents Corp is primarily active in the medical device industry.
The main competitors of Cytosorbents Corp in the market include companies such as Baxter International Inc., Medtronic plc, and Terumo Corporation. These companies also operate in the medical device industry and offer products and solutions similar to Cytosorbents Corp's blood purification technology. Cytosorbents Corp distinguishes itself through its innovative CytoSorb® therapy, which efficiently removes toxins and cytokines from the bloodstream, providing better patient outcomes. Despite the competitive landscape, Cytosorbents Corp continues to stand out as a leader in the field with its unique and effective medical technology.
Cytosorbents Corp is a renowned biotechnology company specializing in blood purification. Founded in 1997, the company has steadily evolved into a global leader in critical care immunotherapy. Cytosorbents Corp focuses on developing and commercializing proprietary products, such as the CytoSorb therapy, which uses its innovative blood purification technology to treat severe inflammation, sepsis, and other life-threatening conditions. With a passion for improving patient outcomes, Cytosorbents Corp has formed strategic partnerships and gained regulatory approvals worldwide. The company's commitment to innovation and its dedication to addressing unmet medical needs position Cytosorbents Corp as a significant player in the biotechnology industry.
Cytosorbents Corp has achieved several significant milestones. The company successfully obtained FDA approval for its flagship product, CytoSorb, which is a blood purification technology used to treat critically-ill patients. It has also received regulatory clearances in various countries, expanding its global presence. Cytosorbents Corp has partnered with renowned medical institutions and established strategic collaborations with industry leaders. The company continually invests in research and development, leading to multiple patents and groundbreaking innovations. With its persistent dedication, Cytosorbents Corp has revolutionized the field of blood purification, improving patient outcomes and solidifying its position as a leader in the industry.
Cytosorbents Corp is primarily present in multiple countries and regions worldwide. The company is based in the United States (US) and has a significant presence across North America. It has also expanded its operations and established a strong presence in Europe, particularly in countries like Germany, France, and Italy. Additionally, Cytosorbents Corp operates in Asia, with a focus on countries such as Japan and China. The company's global presence allows it to serve a wide range of markets and provide its innovative medical technologies and products internationally.
Cytosorbents Corp represents a commitment to improving patient outcomes through innovative medical technology. The company's core values include dedication to clinical excellence, patient-centric care, and continuous innovation. Cytosorbents Corp's corporate philosophy revolves around providing advanced therapies and solutions to treat life-threatening conditions, such as sepsis and organ failure. With a focus on research and development, the company strives to develop and commercialize cutting-edge medical devices that can revolutionize the field of healthcare. Through its efforts, Cytosorbents Corp aims to make a significant impact on patient care and contribute to the advancement of medical science.
Analyytikot asettavat tällä hetkellä Cytosorbents-osakkeelle keskimääräisen tavoitehinnan 5,36 USD (mediaani: 5,10 USD), mikä merkitsee +18,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
6 analyytikkoa arvioi tällä hetkellä Cytosorbents-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Cytosorbents-yhtiöltä 38,88 M USD liikevaihtoa ja −3,81 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Cytosorbents-osake noteerataan hintaan 4,07 EUR (4,54 USD).
Cytosorbents-osake (CTSO) on listattuna 5 pörssissä, muun muassa: NASDAQ (CTSO), SIX (Zürich) (HQE1.SW), Frankfurt (HQE1.F), München (HQE1.MU), Düsseldorf (HQE1.DU).
Cytosorbents Corp is a company specializing in the development and distribution of products for blood detoxification. Its business model is based on three pillars: product sales, licensing of technologies, and collaboration with partners. The company's main product line is Cytosorb, an extracorporeal system for the removal of toxins and inflammatory mediators from the blood. It sells its products mainly to hospitals and medical facilities worldwide. The company also focuses on product and technology development, working closely with medical and research institutions to explore new applications of Cytosorb. It has a strong patent portfolio and strategic partnerships with companies such as Fresenius Medical Care, Medtronic, and Oxiris. The company has also expanded into the veterinary medicine market through its subsidiary Vetco. It has experienced strong growth in recent years, with double-digit revenue increases and improved profit margins. The company is optimistic about the future and believes that the demand for its products will continue to grow, supported by new applications, expansion into the veterinary medicine market, and its strong patent position.
odotettu liikevaihto Cytosorbents on 38,88 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Cytosorbents on −11,98 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Cytosorbents:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,19. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cytosorbents-osakkeen arvostusta.
Cytosorbents:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,37. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cytosorbents-osakkeen arvostuskennuslukuna.
Cytosorbents:n Eulpool-laatuscore on 3/10.
Cytosorbents:n ISIN on US23283X2062. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Cytosorbents:n WKN on A12GDU. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Cytosorbents:n ticker on CTSO. Tämä pörssinoteeraus käytetään Cytosorbents-osakkeiden kauppaan pörssissä.
Cytosorbents osake
Cytosorbents vertaisryhmä
Cytosorbents Ticker
Cytosorbents FIGI
Kaikki tunnusluvut ja syvällinen analyysi Cytosorbents:sta
Meidän osakeanalyysimme Cytosorbents-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Cytosorbents:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: